Invest in EPR-Technologies for Accredited Investors
Accredited Investors can NOW Invest in our Post Money SAFE with the following terms:
- 20% Discount
- Valuation CAP
- Pro Rata Option
- Additional 5% Discount (early Investors)
Additional Options for Accredited Investors to Invest in EPR-Technologies, Inc.:
- SAFE (Simple Agreement for Future Equity) for individual investor
- SAFE via Special Purpose Vehicle (SPV) for multiple individual investor
- Direct Equity Investment via the Company
- Other options including warrants
Accredited Investors
Start Investment
Questions?
email us: investors@epr-technologies.com
Contact Us
Over $18M has been Invested by the US Army and Navy for EPR Research and Clinical Trials
Have more questions, before you invest?
Schedule your Office Hours
A Life-Saving Breakthrough in Emergency Medicine
Follow the links below to learn more about EPR-Technologies, Inc
The Benefits of Investing in EPR-TEchnologies, Inc
Rapid Growth Potential
EPR-Technologies is expected to grow rapidly in the next 5 years. The company is currently in the pre-revenue stage but is expected to generate over $150 million in revenue in less than 5 years. The company is also expected to generate a profit margin of 16.5% and exceed $540 million in value within 5 years.
Large Addressable Market
The global market for EPR is estimated to be worth approximately $36 billion annually. EPR-Technologies is positioned to capture a significant share of this market opportunity.
Strong Management Team
EPR-Technologies is led by a team of experienced professionals with a proven track record in the emergency medicine industry. The team has a deep understanding of the challenges facing patients with critical conditions, failed CPR, and the solutions that can help them.
On Track for Regulatory Approvals
The US Army Research and Development Command has contributed $17.75 million to the University of Pittsburgh, Safar Center for Resuscitation Research for the development of EPR technology. Animal studies of EPR have already been completed with favorable outcomes, leading to the initiation of clinical trials at the R. Adams Cowley Shock Trauma Center in Baltimore and the Cook County Hospital in Chicago. These trials are projected to conclude satisfactorily in late 2023.
Unique Break-Through Technologies
EPR-Technologies has developed a patented technology that uses rapid, profound hypothermia to buy time for critical surgical repairs and medical interventions to save lives in cases where CPR has failed. This technology is not currently available on the market, and it has the potential to revolutionize the way that emergency medicine is practiced.
We would love to hear from you!
Have a question? We’re here to help. Send us a message and we’ll get be in touch.